

30 October 2018

ASX Code: MXC

## MXC partner with Epilepsy Action Australia to launch medical cannabis education platform

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

- MXC collaborates with Epilepsy Action Australia to design and build an online education platform for medicinal cannabis and epilepsy
- The Platform will be designed for the everyday use of healthcare professionals and epilepsy patients, as a gateway to knowledge on epilepsy and access to medical cannabis treatments
- Showcases MXC's commitment to providing education and improving the lives of epilepsy sufferers
- MXC committed to finance phase one of the project with Epilepsy Action Australia
- Phase one of the project will be presented at the CannaTech conferences, hosted in Sydney between 28<sup>th</sup> – 30<sup>th</sup> October

**MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”)** is pleased to announce it has partnered with Epilepsy Action Australia (EAA) to create an online platform dedicated to providing information and education on medicinal cannabis and epilepsy.

The platform will take the form of an EAA website and is designed as an effective online educational tool that provides easily packaged, accessible, user-friendly information about epilepsy and medicinal cannabis.

The platform is intended for healthcare practitioners and patients suffering from epilepsy and will provide information via its ‘Get Educated’ and ‘Get Access’ portals. These portals will consist of news, research breakthroughs and information on how to access medicinal cannabis treatments and clinical trials.

The website will be populated by epilepsy and pharmaceutical experts and phase one of the project will be presented at the CannaTech conference on the 28<sup>th</sup> – 30<sup>th</sup> October in Sydney.

The Company has committed to finance phase one of the EAA project and design and development has already commenced.

## Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented

“I am delighted to announce we have everything in place to begin the design and development of our education project in collaboration with Epilepsy Action Australia. We are dedicated to improving the lives of epilepsy sufferers and will continue to research, develop and progress the clinical epilepsy market.”

## Carol Ireland, CEO and Managing Director of Epilepsy Action Australia commented

“Epilepsy patients are always looking for reliable and trusted information and new research and we have noticed an influx of patients seeking information on medical cannabis. Partnering with MGC Pharma and launching the platform will allow us to provide patients with a portal to access all the information they need to help them better understand what options and alternatives are available to them.”

--Ends--

### For further information, please contact:

#### Media Enquiries

Rosa Smith  
Media and Capital Partners  
+61 457 305 047  
[Rosa.smith@mcpartners.com.au](mailto:Rosa.smith@mcpartners.com.au)

#### MGC Pharmaceuticals Ltd

Brett Mitchell  
Executive Chairman  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels   